DeepMed Research

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Anti-Tac for Treatment of Leukemia

Phase 1

Completed

Conditions: T Cell Leukemia
HTLV-I Infection

Interventions: Biological: daclizumab

First Posted Date: 2000-01-19

Last Posted Date: 2012-08-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 34

Registration Number: NCT00001941

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Hydroxyurea to Treat Beta-Thalassemia (Cooley's Anemia)

Phase 2

Completed

Conditions: Beta Thalassemia
Hemoglobinopathy

First Posted Date: 2000-01-19

Last Posted Date: 2008-03-04

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 100

Registration Number: NCT00001958

Locations: 🇺🇸
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, Maryland, United States

A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas

Phase 2

Completed

Conditions: Ewing's Sarcoma
Rhabdomyosarcoma

First Posted Date: 1999-11-04

Last Posted Date: 2019-11-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00001564

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Diffuse Large B-Cell Lymphoma (DLBCL)
Primary Mediastinal Large B-cell Lymphoma
Burkitt Lymphoma
Anaplastic Large-Cell Lymphoma
Gray Zone Lymphoma

Interventions: Drug: EPOCH
Biological: Rituximab

First Posted Date: 1999-11-04

Last Posted Date: 2024-06-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 348

Registration Number: NCT00001337

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸
Holy Cross Hospital, Fort Lauderdale, Fort Lauderdale, Florida, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

and more 2 locations

Long-Term Therapy With Ribavirin for Chronic Hepatitis C

Phase 4

Completed

Conditions: Chronic Hepatitis C

First Posted Date: 1999-11-04

Last Posted Date: 2017-07-02

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 50

Registration Number: NCT00001854

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Studies of Elevated Parathyroid Activity

Phase 2

Completed

Conditions: MEN1
Hypercalcemia
Parathyroid Neoplasm
Hyperparathyroidism
Multiple Endocrine Neoplasia

Interventions: Drug: 68Ga-Dotatate
Drug: 18F-DOPA

First Posted Date: 1999-11-04

Last Posted Date: 2022-06-07

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 1553

Registration Number: NCT00001277

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas

Phase 2

Completed

Conditions: Ewing's Sarcoma
Rhabdomyosarcoma

Interventions: Biological: therapeutic autologous dendritic cells
Drug: indinavir sulfate
Procedure: peripheral blood stem cell transplantation

First Posted Date: 1999-11-04

Last Posted Date: 2012-06-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 42

Registration Number: NCT00001566

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Evaluation, Treatment, and Natural History of Children and Young Adults With Cancer or Rare Diseases

Completed

Conditions: Lymphoma
Leukemia
Rhabdomyosarcoma
Ewing's Sarcoma
Brain Tumors

First Posted Date: 1999-11-04

Last Posted Date: 2020-09-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 482

Registration Number: NCT00001686

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer

Phase 2

Completed

Conditions: Zollinger Ellison Syndrome
Islet Cell Adenoma

First Posted Date: 1999-11-04

Last Posted Date: 2017-07-02

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 50

Registration Number: NCT00001228

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines

Phase 1

Completed

Conditions: B Cell Lymphoma
Follicular Lymphoma
Lymphoma

First Posted Date: 1999-11-04

Last Posted Date: 2017-07-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 42

Registration Number: NCT00001512

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy